Optimize drug therapy and monitor patient adherence.
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
New York DOH Approval Status
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Plain red. Also acceptable: Lavender (EDTA), pink (K2EDTA), green (sodium heparin), gray (sodium fluoride/potassium oxalate). Avoid use of separator tubes and gels.
Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
After separation from cells: Ambient: 48 hours; Refrigerated: 1 month; Frozen: 6 months
Effective November 15, 2021
|Therapeutic Range||30-60 µg/mL|
|Toxic Level||Greater than or equal to 100 µg/mL|
Felbamate is indicated for treatment of epilepsy. The therapeutic range is based on serum, predose (trough) draw collection at steady-state concentration. Patient pharmacokinetics may be variable due to age, co-medications, and/or compromised renal function. Adverse effects may include nausea, vomiting, dizziness, blurred vision and ataxia. Felbamate use may increase the incidence of liver failure and aplastic anemia.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|